Last Updated : June 20, 2024
Details
Generic Name:
momelotinib
Project Status:
Received
Therapeutic Area:
Myelofibrosis
Manufacturer:
GlaxoSmithKline Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
PC0355-000
Call for patient/clinician input closed:
Tumour Type:
Other
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Momelotinib is indicated for the treatment of disease-related splenomegaly or symptoms, and anemia in adult patients with primary myelofibrosis, post polycythemia vera myelofibrosis or post essential thrombocythemia myelofibrosis who are Janus Kinase (JAK) inhibitor naïve or have been treated with a JAK inhibitor.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Momelotinib is indicated for
the treatment of disease-related splenomegaly or symptoms, and anemia in adult
patients with primary myelofibrosis, post polycythemia vera myelofibrosis or
post essential thrombocythemia myelofibrosis who are Janus Kinase (JAK)
inhibitor naïve or have been treated with a JAK inhibitor.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 09-May-24 |
|---|---|
| Call for patient/clinician input closed | 28-Jun-24 |
| Submission received | 19-Jun-24 |
| Submission accepted | - |
Last Updated : June 20, 2024